title: Evaluation of prognostic factors in AML. Preface.
authors: Jacob M
authors: JM
authors: Rowe
mesh_terms: D000368:Aged; D000617:Aminoglycosides / Q000008:administration & dosage / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D022762:CCAAT-Enhancer-Binding Proteins / Q000235:genetics*; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use; D004248:DNA (Cytosine-5-)-Methyltransferases / Q000235:genetics*; D000090205:DNA Methyltransferase 3A; D005060:Europe / Q000453:epidemiology; D000079982:Gemtuzumab; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics / Q000401:mortality / Q000473:pathology; D008875:Middle Aged; D009154:Mutation; D011379:Prognosis; D016019:Survival Analysis; D014481:United States / Q000453:epidemiology
chemical_list: D000617:Aminoglycosides; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D022762:CCAAT-Enhancer-Binding Proteins; C515848:CEBPA protein, human; C000717967:DNMT3A protein, human; D003561:Cytarabine; D000079982:Gemtuzumab; D004248:DNA (Cytosine-5-)-Methyltransferases; D000090205:DNA Methyltransferase 3A